Table 4.
Multivariable Analysis of COVID-19 Mortality in Patients With COVID-19 Breakthrough Infection
| Covariate | OR | 95% CI | P |
|---|---|---|---|
| Male sex | 0.720 | 0.250–2.13 | .558 |
| Age | 1.06 | 1.02–1.11 | .006 |
| Health care worker | 1.03 | 0.100–10.5 | .979 |
| Smoking history | 1.07 | 0.360–3.20 | .907 |
| Chronic kidney disease | 1.21 | 0.310–4.76 | .787 |
| COPD | 1.73 | 0.550–5.42 | .347 |
| Diabetes mellitus | 0.870 | 0.270–2.82 | .812 |
| Cardiovascular disease | 2.83 | 0.730–11.0 | .131 |
| Hypertension | 0.640 | 0.200–2.10 | .463 |
| Immunocompromised | 0.870 | 0.300–2.52 | .793 |
| Vaccine type | |||
| JNJ78436735 | 1.21 | 0.190–7.83 | .843 |
| mRNA1273 | 0.970 | 0.310–3.06 | .955 |
| BNT162b2 | 0.360 | 0.145–0.898 | .029 |
Significant P values are bolded. Number of observations in the original data set = 982. Number of observations used = 970; 12 patients excluded due to death from non-COVID-19-related events.
Abbreviations: BNT162b2, Pfizer vaccine; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; JNJ78436735, Janssen vaccine; mRNA1273, Moderna vaccine; OR, odds ratio.